A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/ salmeterol in moderate to very severe COPD

European Respiratory Journal

Volumn 43, Issue 3, 2014, Pages 763-772

  Agusti, Alvar ^a,b   De Teresa, Luis ^c   De Backer, Wilfried ^d   Zvarich, Michael T ^e   Locantore, Nicholas ^e   Barnes, Neil ^f   Bourbeau, Jean ^g   Crim, Courtney ^e  

^a HOSPITAL CLÍNIC   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c Medicina Innovadora Clinica Mediterranea de Neurociencias   (Spain)

^d ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^e GLAXOSMITHKLINE   (United States)

^f LONDON CHEST HOSPITAL   (United Kingdom)

^g MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FLUTICASONE FUROATE PLUS VILANTEROL; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; GLUCOSE; IPRATROPIUM BROMIDE; MUCOLYTIC AGENT; OXYGEN; PLACEBO; SALBUTAMOL; SALMETEROL; TIOTROPIUM BROMIDE;

ADULT; ANGINA PECTORIS; ARTICLE; BACKACHE; BONE DISEASE; BRADYCARDIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; COUGHING; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHONIA; EYE DISEASE; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HEALTH STATUS; HEART ATRIUM FIBRILLATION; HEART DISEASE; HUMAN; HYPERSENSITIVITY; HYPERTENSION; LOWER RESPIRATORY TRACT INFECTION; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORNING DOSAGE; MULTICENTER STUDY; OROPHARYNX CANDIDIASIS; OROPHARYNX PAIN; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; ST. GEORGE RESPIRATORY QUESTIONNAIRE; TACHYCARDIA; THRUSH; TREMOR; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADULT; AGED; ALBUTEROL; ANDROSTADIENES; ANTI-INFLAMMATORY AGENTS; BENZYL ALCOHOLS; BRONCHODILATOR AGENTS; CHLOROBENZENES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRES; RESPIRATORY FUNCTION TESTS; SEVERITY OF ILLNESS INDEX; SMOKING; TREATMENT OUTCOME;

EID: 84895548677     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00054213     Document Type: Article

References (38)

1. Mahler DA, Wire P, Horstman D, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166: 1084-1091.
2. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-789.
3. Kardos P, Wencker M, Glaab T, et al. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 144-149.
4. Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008; 178: 332-338.
5. Price D, Robertson A, Bullen K, et al. Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label study. BMC Pulm Med 2010; 10: 1.
6. Restrepo RD, Alvarez MT, Wittnebel LD, et al. Medication adherence issues in patients treated for COPD. Int J Chron Obstruct Pulmon Dis 2008; 3: 371-384.
7. Vestbo J, Anderson JA, Calverley PM, et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax 2009; 64: 939-943.
8. Biggadike K, Bledsoe RK, Hassell AM, et al. X-ray crystal structure of the novel enhanced-affinity glucocorticoid agonist fluticasone furoate in the glucocorticoid receptor-ligand binding domain. J Med Chem 2008; 51: 3349-3352.
9. Slack RJ, Barrett VJ, Morrisson VS, et al. In vitro pharmacological characterization of vilanterol, a novel long-acting b2-adrenoceptor agonist with 24-hour duration of action. J Pharmacol Exp Ther 2013; 344: 218-230.
10. Procopiou PA, Barrett VJ, Bevan NJ, et al. Synthesis and structure-activity relationships of long-acting b2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approach. J Med Chem 2010; 53: 4522-4530.
11. Harrell AW, Siederer SK, Bal J, et al. Metabolism and disposition of vilanterol, a long-acting b2-adrenoceptor agonist for inhalation use in humans. Drug Metab Dispos 2013; 41: 89-100.
12. Hanania NA, Feldman G, Zachgo W, et al. The efficacy and safety of the novel long-acting b2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial. Chest 2012; 142: 119-127.
13. Bateman ED, Bleecker ER, Lötvall J, et al. Dose effect of once-daily fluticasone furoate in persistent asthma: a randomized trial. Respir Med 2012; 106: 642-650.
14. Bleecker ER, Bateman ED, Busse WW, et al. Consistently favorable safety profile of fluticasone furoate (FF), a oncedaily (OD) inhaled corticosteroid (ICS), across a range of treatment steps in patients with uncontrolled asthma. Am J Respir Crit Care Med 2011; 183: A1300.
15. Busse WW, Bleecker ER, Bateman ED, et al. Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial. Thorax 2011; 67: 35-41.
16. Woodcock A, Bleecker ER, Busse WW, et al. Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma. Respir Res 2011; 12: 160.
17. Sterling R, Lim J, Frith L, et al. Efficacy and optimal dosing interval of the long-acting b2 agonist, vilanterol, in persistent asthma: a randomised trial. Respir Med 2012; 106: 1110-1115.
18. Boscia JA, Pudi KK, Zvarich MT, et al. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study. Clin Ther 2012; 34: 1655-1666.
19. Kerwin EM, Scott-Wilson C, Sanford L, et al. A randomised trial of fluticasone furoate/vilanterol (50/25 mg; 100/25 mg) on lung function in COPD. Respir Med 2013; 107: 560-569.
20. Martinez FJ, Boscia J, Feldman G, et al. Fluticasone furoate/vilanterol (100/25; 200/25 mg) improves lung function in COPD: a randomised trial. Respir Med 2013; 107: 550-559.
21. Dransfield MT, Bourbeau B, Jones PW, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med 2013; 1: 210-223.
22. Celli BR, MacNee W ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932-946.
23. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005; 26: 319-338.
24. Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008; 31: 416-469.
25. Donohue JF. Minimal clinically important differences in COPD lung function. COPD 2005; 2: 111-124.
26. Jones PW. St. George's Respiratory Questionnaire: MCID. COPD 2005; 2: 75-79.
27. Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013; 187: 347-365.
28. Anzueto A. Impact of exacerbations on COPD. Eur Respir Rev 2010; 19: 113-118.
29. Meguro M, Barley EA, Spencer S, et al. Development and validation of an improved, COPD-specific version of the St. George Respiratory Questionnaire. Chest 2007; 132: 456-463.
30. Chapman KR, Rennard SI, Dogra A, et al. Long-term safety and efficacy of indacaterol, a long-acting b2-agonist, in patients with COPD: a randomized, placebo-controlled study. Chest 2011; 140: 68-75.
31. Tashkin DP, Doherty DE, Kerwin E, et al. Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in patients with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials. Int J Chron Obstruct Pulmon Dis 2012; 7: 73-86.
32. Agusti A, Hedner J, Marin JM, et al. Night-time symptoms: a forgotten dimension of COPD. Eur Respir Rev 2011; 20: 183-194.
33. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomized controlled trial. Lancet 2003; 361: 449-456.
34. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23: 1296-1310.
35. Breekveldt-Postma NS, Penning-van Beest FJ, Siiskonen SJ, et al. The effect of discontinuation of antihypertensives on the risk of acute myocardial infarction and stroke. Curr Med Res Opin 2008; 24: 121-127.
36. Bourbeau J, Bartlett SJ. Patient adherence in COPD. Thorax 2008; 63: 831-838.
37. Lareau SC, Yawn BP. Improving adherence with inhaler therapy in COPD. Int J Chron Obstruct Pulmon Dis 2010; 5: 401-406.
38. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2012. www.ginasthma.org/documents/4 Date last updated: December 2012. Date last accessed: January 30, 2013.